Home About us Contact
|
Home About us Contact | ||
|
|
||
Electrolyte Balance (electrolyte + balance)
Selected AbstractsTransgenic mice for studies of the renin,angiotensin system in hypertensionACTA PHYSIOLOGICA, Issue 4 2004J. L. Lavoie Abstract Hypertension is a polygenic and multi-factorial disorder that is extremely prevalent in western societies, and thus has received a great deal of attention by the research community. The renin,angiotensin system has a strong impact on the control of blood pressure both in the short- and long-term, making it one of the most extensively studied physiological systems. Nevertheless, despite decades of research, the specific mechanisms implicated in its action on blood pressure and electrolyte balance, as well as its integration with other cardiovascular pathways remains incomplete. The production of transgenic models either over-expressing or knocking-out specific components of the renin,angiotensin system has given us a better understanding of its role in the pathogenesis of hypertension. Moreover, our attention has recently been refocused on local tissue renin,angiotensin systems and their physiological effect on blood pressure and end-organ damage. Herein, we will review studies using genetic manipulation of animals to determine the role of the endocrine and tissue renin,angiotensin system in hypertension. We will also discuss some untraditional approaches to target the renin,angiotensin system in the kidney. [source] Untersuchungen an wachsenden Schweinen zum Futterwert einer neuen Ackerbohnensorte (Vicia faba L.) bei Ergänzung mit DL -Methionin oder DL -Methionin-HydroxyanalogJOURNAL OF ANIMAL PHYSIOLOGY AND NUTRITION, Issue 1-2 2002HJ. ABEL Investigations in growing pigs on the feeding value of a new cultivar of field beans (Vicia faba L.) supplemented with DL -methionine or DL -methionine-hydroxyanalogue A basal control mixture of barley, soy bean meal and soy bean oil was replaced by 25% of the new field bean-cultivar `Divine' and the resulting two mixtures were supplemented with minerals, trace elements, vitamins and amino acids according to the ideal protein concept. The control diet was adjusted with DL -methionine (DL -Met), the field bean mixture either with DL -Met or DL -methionine-hydroxyanalogue (DL -MHA) assuming biological equivalence on a molar basis for both supplements. The three experimental diets were fed to growing pigs (35,40 kg bwt.). Spontaneous urine samples were analysed separately for determining parameters that characterize the acid-base status of the pigs. There were no significant differences between experimental groups in nutrient digestibilities. The level of bacterially fermentable substances was increased in the diets containing field beans. The field beans contained 14 mg ME/kg DM. There were no significant (p < 0,05) differences in N- and mineral-retentions (Ca, P, Na, K) between the treatments. The stronger alkalinity found in urine after feeding the field bean mixtures resulted from a higher electrolyte balance of the diet. Eine Kontrollration aus Gerste, Sojaschrot und Sojaöl wurde zu 25% durch Ackerbohnen der neugezüchteten Sorte `Divine' ersetzt und beide Mischungen mit Mineral- und Wirkstoffen sowie Aminosäuren ergänzt. Die Ergänzung mit Methionin erfolgte in der Kontrollmischung mit DL -Methionin, in der Ackerbohnenmischung mit DL -Methionin (DL -Met) oder DL -Methionin-Hydroxyanalog (DL -MHA) unter Zugrundelegung der molaren Wirkungsäquivalenz der beiden Supplemente. Die resultierenden drei Futtermischungen wurden in Stoffwechselversuchen an Schweine (35,40 kg LM) gefüttert. Separate Spontanharnproben wurden auf Parameter des Säure-Basen-Haushalts der Tiere untersucht. Zwischen den Versuchsgruppen traten keine signifikanten Unterschiede in den Nährstoffverdaulichkeiten auf. Die Gehalte an bakteriell fermentierbarer Substanz wurden durch Ackerbohnen erhöht. Der Gehalt der Ackerbohnen an umsetzbarer Energie lag bei 14 MJ ME/kg T. Die N- und Mineralstoffretentionen (Ca, P, Na, K) der Schweine unterschieden sich zwischen den Fütterungsgruppen nicht signifikant (p < 0,05). Die bei Ackerbohnenfütterung gesteigerte Harn-Alkalität ließ sich auf erhöhte kaliumbedingte Elektrolytbilanzen des Futters zurückführen. [source] Variability in incubator humidity practices in the management of preterm infantsJOURNAL OF PAEDIATRICS AND CHILD HEALTH, Issue 9 2009Lynn Sinclair Aim: To determine current practice and opinion in relation to incubator humidity use in the management of preterm infants in neonatal intensive care units (NICU's) within the Australian and New Zealand Neonatal Network (ANZNN). Methods: A survey was conducted in 26 NICU's in the ANZNN. A senior clinical nurse in each perinatal centre participated in a telephone survey that focused on local humidification practices and on the clinicians' views and experiences of humidity use. Results: All centres routinely used supplemental humidity in the management of preterm infants. The majority of centres (77%) had written protocols to guide practice. Eighty-eight per cent commenced humidity at a high level (relative humidity , 80%). There was wide practice variation in the gestational age parameters determining humidification use (all gestational ages up to 37 weeks), duration of use (3,77 days), timing of initiation (admission to 72 h after birth) and weaning practices. Perceived benefits of humidification included improved thermoregulation, skin integrity, and fluid and electrolyte balance and reduced transepidermal water loss. Perceived risks included sepsis and hyperthermia. Conclusions: Our study confirmed that incubator humidity is used routinely in the management of preterm infants in the ANZNN. Wide variation in humidification practices across NICUs reflects the paucity of research evidence. Perceived benefits and risks of humidity use were consistent with available literature. To optimise the care environment and provide an evidence base for practice further research is warranted. [source] The Coxib NSAIDs: Potential Clinical and Pharmacologic Importance in Veterinary MedicineJOURNAL OF VETERINARY INTERNAL MEDICINE, Issue 5 2005Mary Sarah Bergh Nonsteroidal anti-inflammatory drugs (NSAIDs) are used to control acute and chronic pain as well as to manage oncologic and neurologic diseases in human and veterinary patients. Despite ongoing research and efforts to improve the safety and efficacy of existing drugs, adverse effects such as gastrointestinal irritation, renal and hepatic toxicity, interference with hemostasis, and reproductive problems persist. The true incidence of NSAID-induced adverse effects in animals is unknown, but is likely underestimated, because cats and dogs may be more sensitive than humans to NSAIDs due to alterations in drug metabolism, absorption, and enterohepatic recirculation. NSAIDs produce both analgesia and toxic adverse effects primarily by inhibiting cyclooxygenase (COX), thereby decreasing the production of prostaglandins that signal inflammation and pain as well as mediate physiologic functions such as platelet aggregation, gastric protection, and electrolyte balance in the kidney. The presence of at least 2 COX isoforms may account for variability in NSAID efficacy and toxicity both within and among species. This paper reviews and evaluates the published literature on the safety, pharmacology, uses, and complications of a subclass of COX-1,sparing drugs, the coxibs, in veterinary medicine. Coxibs and other COX-1,sparing drugs provide a clinically useful improvement over traditional NSAIDs, but data are incomplete and more in vivo species-specific, target-tissue, and clinical studies are needed. [source] An Overview of SR121463, a Selective Non-Peptide Vasopressin V2 Receptor AntagonistCARDIOVASCULAR THERAPEUTICS, Issue 3 2001C. Serradeil-Le Gal ABSTRACT SR121463 is a selective, orally active, non-peptide antagonist of vasopressin (AVP) V2 receptors with powerful aquaretic properties in various animal species and humans. SR121463 belongs to a new class of drugs, called aquaretics, which are capable of inducing free-water excretion without affecting electrolyte balance. SR121463 displays high affinity for animal and human V2 receptors and exhibits a remarkably selective V2 receptor profile. SR121463 and [3H]SR121463 are used, therefore, as selective probes for characterization and labeling of V2 receptors. In various functional studies in vitro, SR121463 behaves as a potent antagonist. It inhibits AVP-stimulated human renal adenylyl cyclase and dDAVP (1-desamino, 8-D arginine-vasopressin)-induced relaxation of rat aorta. SR121463 also behaves as an inverse agonist in cells expressing a constitutively activated human V2 receptor mutant. In vitro, SR1 21463 rescued misfolded V2 AVP receptor mutants by increasing cell surface expression and restoring V2 function. In normally hydrated conscious rats, dogs and monkeys, SR121463, by either i.v. or p.o. administration, induced a dose-dependent aquaresis with no major changes in urinary Na+ and K+ excretion (unlike classical diuretics). In cirrhotic rats with ascites and impaired renal function, a 10-day treatment with SR121463 totally corrected hyponatremia and restored normal urine excretion. In a model of diabetic nephropathy in rats, SR121463 strongly reduced albumin excretion. SR121463 was also effective at extrarenal V2 (or V2 -like) receptors involved in vascular relaxation or clotting factor release in vitro and in vivo. In the rabbit model of ocular hypertension, SR121463 by either single or repeated instillation, decreased intraocular pressure. After acute and chronic administration to rats, dogs or healthy human volunteers, SR121463 was well absorbed and well tolerated. In all species studied the drug produced pronounced aquaresis without any agonist effect. Thus, SR121463 is a potent, orally active and selective antagonist at V2 receptors with powerful aquaretic properties. It is a useful tool for further exploration of function of renal or extrarenal V2 receptors. Pure V2 receptor antagonists are likely to be therapeutically useful in several water-retaining diseases such as hyponatremia, Syndrome of Inappropriate Antidiuretic Hormone secretion (SIADH), congestive heart failure, liver cirrhosis, and other disorders possibly mediated by V2 receptors (e.g., glaucoma). [source] | |||||||||||||